QDP401

QDP401 is an investigational drug candidate currently in development by RestoriT, Inc., a biotechnology company focused on urological health. Positioned within the company's early-stage pipeline, the compound is intended for applications in the field of urology. As of early 2025, specific details regarding its chemical structure, molecular target, and mechanism of action remain proprietary and have not been publicly disclosed. RestoriT's broader research focus centers on restoring physiological function in urological conditions, such as erectile dysfunction and bladder disorders, suggesting that QDP401 is designed to address unmet needs in these or related therapeutic areas.